Analytical Data
-
Gene name
Coagulation Factor XII/F12
- Application
-
Alternative Names
FXII; HAF; Contact Factor; Hageman Factor
-
Species
Rat
-
Source
E. coli
-
Tag
Two N- s, His- & SUMO-
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0A0H2UI19
-
Expression Region
Val354~Phe595
-
Molecular Weight
40kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Coagulation Factor XII (F12) is a crucial protein in the blood coagulation cascade, playing a significant role in initiating both the intrinsic pathway of coagulation and the fibrinolytic system. Its activation can lead to thrombosis; however, it also has implications in inflammation, wound healing, and host defense. Research into recombinant forms of Factor XII has gained traction due to the potential for therapeutic applications in managing bleeding disorders and thrombotic diseases. Recombinant Factor XII could offer advantages over plasma-derived products, such as reduced risk of pathogen transmission, consistent quality, and the ability to modify its properties for enhanced efficacy. Studies have also demonstrated that modulating Factor XII activity might offer a novel approach for treating hypercoagulable states without affecting hemostasis, thereby presenting an opportunity to develop targeted therapies. Understanding the structure-function relationship of Factor XII through recombinant protein studies can provide insights into its mechanisms of action and pave the way for innovative treatments in coagulation disorders. As research advances, the therapeutic potential of recombinant Factor XII continues to be explored, highlighting the importance of this protein in both basic and applied biomedical research.
